MARVIN MOSER, M.D.
The Direct Cost involved in the treatment of hypertension in the United States has been estimated at approximately $8 billion a year, with more than $1.5 billion being spent on antihypertensive drugs (1). Recent surveys have reported that a significant number of patients with hypertension (20% to 35%) find the cost of drugs to be an obstacle to treatment (2-4). This number has increased during the past 3 to 4 years because newer, more expensive, and heavily promoted drugs have become available. The cost may also have increased further as pressure mounted to use newer forms of technology in the
Learn more about subscription options.
Register Now for a free account.
MOSER M. "Cost Containment" in the Management of Hypertension. Ann Intern Med. 1987;107:107–109. doi: 10.7326/0003-4819-107-1-107
Download citation file:
Published: Ann Intern Med. 1987;107(1):107-109.
Cardiology, Coronary Risk Factors, Healthcare Delivery and Policy, HIV, Hypertension.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only